» Authors » Alexander M Spence

Alexander M Spence

Explore the profile of Alexander M Spence including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 1213
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Blumenthal D, Rankin C, Stelzer K, Spence A, Sloan A, Moore Jr D, et al.
Int J Clin Oncol . 2014 Nov; 20(4):650-8. PMID: 25407559
Aims: To determine the efficacy of methylguanine methyltransferase (MGMT) depletion + BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy and the impact of methylation status in adults with glioblastoma multiforme (GBM) and gliosarcoma....
2.
OSullivan F, Muzi M, Mankoff D, Eary J, Spence A, Krohn K
Ann Appl Stat . 2014 Nov; 8(2):1065-1094. PMID: 25392718
Most radiotracers used in dynamic positron emission tomography (PET) scanning act in a linear time-invariant fashion so that the measured time-course data are a convolution between the time course of...
3.
Mrugala M, Crew L, Fink J, Spence A
Oncol Lett . 2012 Nov; 4(5):1082-1086. PMID: 23162656
Over 65,000 primary brain tumors are diagnosed annually in the US alone. Malignant gliomas represent more than one-third of such cases. Despite advances in neuroimaging, surgical techniques, radiotherapy and chemotherapy,...
4.
Gu S, Chakraborty G, Champley K, Alessio A, Claridge J, Rockne R, et al.
Math Med Biol . 2011 May; 29(1):31-48. PMID: 21562060
Glioblastoma multiforme (GBM) is a class of primary brain tumours characterized by their ability to rapidly proliferate and diffusely infiltrate surrounding brain tissue. The aggressive growth of GBM leads to...
5.
Couldwell W, Surnock A, Tobia A, Cabana B, Stillerman C, Forsyth P, et al.
Cancer . 2011 Apr; 117(21):4905-15. PMID: 21456013
Background: Hypericin is a potent inhibitor of glioma growth in vitro. To examine whether synthetic oral hypericin can be tolerated by patients with recurrent malignant gliomas (anaplastic astrocytoma and glioblastoma)...
6.
Ramakrishna R, Barber J, Kennedy G, Rizvi A, Goodkin R, Winn R, et al.
Surg Neurol Int . 2010 Sep; 1. PMID: 20847921
Background: A paucity of data exists concerning the prognostic usefulness of preoperative and postoperative imaging after resection of glioblastoma multiforme (GBM). This study aimed to connect outcome with imaging features...
7.
Wang C, Rockhill J, Mrugala M, Peacock D, Lai A, Jusenius K, et al.
Cancer Res . 2009 Nov; 69(23):9133-40. PMID: 19934335
Glioblastomas are the most aggressive primary brain tumors, characterized by their rapid proliferation and diffuse infiltration of the brain tissue. Survival patterns in patients with glioblastoma have been associated with...
8.
OSullivan F, Muzi M, Spence A, Mankoff D, OSullivan J, Fitzgerald N, et al.
J Am Stat Assoc . 2009 Oct; 104(486):556-571. PMID: 19830267
Kinetic analysis is used to extract metabolic information from dynamic positron emission tomography (PET) uptake data. The theory of indicator dilutions, developed in the seminal work of Meier and Zierler...
9.
Szeto M, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord Jr E, et al.
Cancer Res . 2009 Apr; 69(10):4502-9. PMID: 19366800
Glioblastoma multiforme (GBM) are aggressive and uniformly fatal primary brain tumors characterized by their diffuse invasion of the normal-appearing parenchyma peripheral to the clinical imaging abnormality. Hypoxia, a hallmark of...
10.
Spence A, Muzi M, Link J, OSullivan F, Eary J, Hoffman J, et al.
Mol Imaging Biol . 2009 Mar; 11(5):343-55. PMID: 19326172
Purpose: 3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) is being developed for imaging cellular proliferation. The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas...